Thanks Heskumdai, travelbug2 and hottod, I have found the latest timing in the
November AGM CEO's Presentation. Slide 3 made it very clear.
From VP-001, revenue generation is approximately 12 months after the human safety/efficacy stage, so for PYC-001 and VP-002 I simply added 1 year to the human safety/efficacy stage to arrive at the revenue generation date.
Latest estimated timing are as follows:
- H1/2 2025 - US$1-2b VP-001 Treating Retinitis Pigmentosa
- 2025/2026 - US$5b PYC-001 Treating Diabetic Macular Degeneration and Age-related Macular Degeneration
- 2025/2026 - US$1b VP-002 Treating Autosomal Dominant Optic Atrophy (ADOA)
However in PYC's June Corporate Overview slide 6, they have mentioned opportunity to
- 4X more likely to reach market from Phase 1 (45% likelihood for orphan non-oncology); and
- 40% reduction in clinical development timeline with opportunity to combine phases 2 and 3 and obtain accelerated approval.
If both Orphan Drug Designation (ODD) and Rare Paediatric Disease Designation (RPDD) are approved, "
18-24 month when VP-001 is commercialized
" would still be possible. Bringing US$1-2b of income forward by 2 - 2.5 years would have a huge boost on SP. Therefore we sincerely hope PYC would get both approvals in 2021.
The projected income from VP-001 @ 0.72 USD/AUD exchange rate would translate to 42c per share even if divided into the inflated market cap of 3,255M shares when the $55M cap raise is completed!
(20min delay)